Amplia Therapeutics Ltd. (AU:ATX)
ASX:ATX
Want to see AU:ATX full AI Analyst Report?
Top Page
Amplia Therapeutics
(Sydney:ATX)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.15
▲(9.29% Upside)
Action:ReiteratedDate:04/10/26
The score is primarily constrained by weak financial performance—ongoing large losses and persistent (recently higher) cash burn—despite strong gross margins and improving revenue. Technical indicators are broadly neutral, providing limited directional support, while valuation is less favorable due to negative earnings and no dividend yield data.
Positive Factors
Very high gross margins
Amplia's ~90–100% gross margins reflect highly favorable unit economics typical of targeted therapeutics. Durable high gross profitability means incremental revenue can convert efficiently to gross profit, supporting long-term scalability and improved margins as fixed costs are leveraged.
Negative Factors
Persistent and rising cash burn
Operating and free cash flow have been negative each year and cash burn grew in FY2025, eroding runway. Persistent, increasing outflows force reliance on external financing, heighten dilution risk, and constrain strategic flexibility over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Very high gross margins
Amplia's ~90–100% gross margins reflect highly favorable unit economics typical of targeted therapeutics. Durable high gross profitability means incremental revenue can convert efficiently to gross profit, supporting long-term scalability and improved margins as fixed costs are leveraged.
Read all positive factors
Amplia Therapeutics (ATX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$84.66M
Dividend YieldN/A
Average Volume (3M)525.22K
Price to Earnings (P/E)―
Beta (1Y)0.43
Revenue GrowthN/A
EPS Growth26.64%
CountryAU
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding513,071,660
10 Day Avg. Volume444,673
30 Day Avg. Volume525,217
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)1.02
Price to Sales (P/S)5.68
P/FCF Ratio-3.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Amplia Therapeutics Business Overview & Revenue Model
Company Description
Amplia Therapeutics (ATX) is a biotechnology company focused on developing innovative therapies for the treatment of fibrotic diseases and cancer. The company specializes in the discovery and development of small molecule drugs that target the und...
How the Company Makes Money
Amplia Therapeutics generates revenue primarily through partnerships, licensing agreements, and collaborations with large pharmaceutical firms and healthcare organizations. The company leverages its proprietary drug candidates and intellectual pro...
Amplia Therapeutics Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
58
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.38M | 3.78M | 4.45M | 1.19M | 1.98M | 1.53M |
| Gross Profit | 2.20M | 3.57M | 4.01M | 1.12M | 1.98M | 1.53M |
| EBITDA | -10.75M | -6.78M | -4.48M | -7.26M | -3.64M | -3.81M |
| Net Income | -7.93M | -6.57M | -4.50M | -6.24M | -3.64M | -2.28M |
Balance Sheet | ||||||
| Total Assets | 44.54M | 22.94M | 14.85M | 18.68M | 24.48M | 10.88M |
| Cash, Cash Equivalents and Short-Term Investments | 29.16M | 10.86M | 3.39M | 9.26M | 14.61M | 1.85M |
| Total Debt | 381.42K | 13.89K | 1.59M | 2.27M | 2.10M | 0.00 |
| Total Liabilities | 1.61M | 1.91M | 3.43M | 2.85M | 2.64M | 539.13K |
| Stockholders Equity | 42.93M | 21.02M | 11.42M | 15.84M | 21.85M | 10.34M |
Cash Flow | ||||||
| Free Cash Flow | -13.39M | -6.89M | -5.13M | -5.31M | -4.42M | -2.92M |
| Operating Cash Flow | -13.36M | -6.89M | -5.13M | -5.29M | -4.40M | -2.92M |
| Investing Cash Flow | -81.65K | -2.07K | -2.23K | -58.42K | -26.64K | -5.35K |
| Financing Cash Flow | 37.99M | 14.32M | -772.98K | -84.22K | 17.19M | 3.66M |
Amplia Therapeutics Technical Analysis
Positive
0.14
Price Trends
0.15
Positive
0.14
Positive
0.17
Negative
Market Momentum
<0.01
Positive
49.09
Neutral
8.97
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ATX, the sentiment is Positive. The current price of 0.14 is below the 20-day moving average (MA) of 0.18, below the 50-day MA of 0.15, and below the 200-day MA of 0.17, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 49.09 is Neutral, neither overbought nor oversold. The STOCH value of 8.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ATX.
Amplia Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$1.58B | 78.41 | 9.20% | ― | 12.35% | 26.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$84.66M | -3.83 | -24.81% | ― | ― | 26.64% | |
45 Neutral | AU$47.30M | -9.56 | -104.56% | ― | ― | ― | |
42 Neutral | AU$97.13M | -1.51 | -265.55% | ― | -20.79% | 73.98% | |
41 Neutral | AU$97.88M | -2.12 | -30.19% | ― | ― | 63.46% | |
39 Underperform | AU$5.95M | -1.39 | 56.41% | ― | -99.31% | 90.20% |
* Healthcare Sector Average
AU:ATX
Amplia Therapeutics
0.17
0.11
217.31%
AU:ENP
Tryptamine Therapeutics
0.03
>-0.01
-9.37%
AU:NEU
Neuren Pharmaceuticals Limited
12.49
1.96
18.61%
AU:PAR
Paradigm Biopharmaceuticals
0.22
-0.07
-25.86%
AU:ATH
Alterity Therapeutics
0.01
0.00
0.00%
AU:ZLD
Zelira Therapeutics
0.50
0.11
28.21%
Amplia Therapeutics Corporate Events
Amplia Halts New Recruitment in Pancreatic Cancer Trial After Chemo Toxicities
Apr 8, 2026
Amplia Therapeutics has paused further recruitment in its AMPLICITY clinical trial in advanced pancreatic cancer after three dose-limiting toxicities were linked to the chemotherapy regimen mFOLFIRINOX, while confirming no toxicity concerns relate...
Amplia Halts AMPLICITY Recruitment, Shifts Focus to Less Toxic Pancreatic Cancer Regimens
Apr 6, 2026
Amplia Therapeutics has halted further recruitment in its AMPLICITY trial in advanced pancreatic cancer, after three dose-limiting toxicities were linked to the chemotherapy regimen mFOLFIRINOX rather than to its lead drug narmafotinib. Eight pati...
Amplia posts unprecedented complete responses and survival gain in pancreatic cancer trial
Mar 22, 2026
Amplia Therapeutics reported mature data from its Phase 1b/2a ACCENT trial in advanced pancreatic cancer, showing that five patients achieved a complete response when treated with narmafotinib plus gemcitabine-Abraxane, an unprecedented 7.8% compl...
Amplia requests ASX trading halt ahead of key clinical trial data
Mar 19, 2026
Amplia Therapeutics has requested and been granted a trading halt on its ASX-listed securities, effective 19 March 2026, as it prepares to release clinical trial results derived from a central reading of new data. The halt, which is expected to re...
Amplia Therapeutics Reappoints Experienced CFO to Support Biotech Growth
Feb 24, 2026
Amplia Therapeutics has appointed Hamish George as its Chief Financial Officer, effective 25 February 2026, marking his return to the role after previously serving as CFO from October 2021 and succeeding fellow Bio101 Financial Advisory director T...
Amplia Expands U.S. Footprint With New Sites for Pancreatic Cancer Trial
Feb 10, 2026
Amplia Therapeutics has opened two new U.S. clinical sites at the University of California, Irvine and The Cleveland Clinic for its AMPLICITY trial, which evaluates lead FAK inhibitor narmafotinib in combination with modified FOLFIRINOX in newly d...
Amplia Secures Phase 3-Ready Supply with First Large-Scale Narmafotinib Manufacture
Jan 21, 2026
Amplia Therapeutics has completed the first large-scale, GMP-compliant manufacture of narmafotinib, producing about 13 kilograms of active pharmaceutical ingredient and successfully transitioning production from an RD setting to a commercial-ready...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.